No connection

Search Results

ZJYL

BEARISH
$2.15 Live
Jin Medical International Ltd. · NASDAQ
$1.64 52W Range $19.3
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 24, 2026
Market cap
$16.87M
P/E
10.78
ROE
4.8%
Profit margin
5.8%
Debt/Equity
0.64
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
ZJYL presents a classic 'value trap' scenario, characterized by a stable Piotroski F-Score of 6/9 and a price significantly below its Graham Number ($4.13), yet plagued by severe fundamental decay. While the company maintains a healthy balance sheet with a current ratio of 1.85 and low debt/equity (0.64), it is suffering from catastrophic growth contraction, with revenue down 16.5% and earnings down 32% YoY. The massive 87.7% decline in share price over the last year reflects a market that has completely lost confidence in the company's growth trajectory. Despite trading at a deep discount to book value (P/B 0.57), the lack of positive catalysts and bearish technical trend outweigh the valuation appeal.

Key Strengths

Trading significantly below book value (P/B 0.57)
Stable financial health indicated by Piotroski F-Score of 6/9
Strong liquidity position with a Current Ratio of 1.85
Manageable leverage with Debt/Equity at 0.64
Positive profit margins (5.76%) relative to a negative sector average

Key Risks

Severe revenue contraction (-16.5% YoY)
Sharp decline in earnings growth (-32% YoY)
Catastrophic 1-year price performance (-87.7%)
Complete lack of analyst coverage and institutional guidance
Bearish technical trend (0/100 score)
AI Fair Value Estimate
Based on comprehensive analysis
$1.75
-18.8% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
36
Weak
Value
85
Future
15
Past
10
Health
70
Dividend
0
AI Verdict
Value Trap
Key drivers: Negative growth metrics, Extreme price depreciation, Strong balance sheet vs. weak income statement
Confidence
90%
Value
85/100

Ref P/E, P/B, and Graham Number

Positives
  • P/E of 10.78 is very low
  • P/B of 0.57 suggests deep discount
  • Price is well below Graham Number of $4.13
Watchpoints
  • Intrinsic value based on growth is only $1.4
Future
15/100

Ref Growth rates

Positives
No standout positives identified.
Watchpoints
  • Revenue growth -16.5%
  • Earnings growth -32%
Past
10/100

Ref Historical trends

Positives
No standout positives identified.
Watchpoints
  • 1Y Change -87.7%
  • 5Y Change -72.9%
Health
70/100

Ref Piotroski F-Score and Liquidity Ratios

Positives
  • Piotroski F-Score 6/9
  • Current Ratio 1.85
  • Low Debt/Equity
Watchpoints
  • Low ROA (0.77%)
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$2.15

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ZJYL and closest competitors.

Updated 2026-04-23
ZJY
Jin Medical International Ltd.
Primary
5Y
-72.9%
3Y
-71.2%
1Y
-87.7%
6M
-68.8%
1M
+11.1%
1W
+7.2%
LPC
Lipocine Inc.
Peer
5Y
-90.5%
3Y
-50.9%
1Y
-23.7%
6M
-23.5%
1M
-67.6%
1W
+22.7%
GNT
Genenta Science S.p.A.
Peer
5Y
-93.8%
3Y
-88.7%
1Y
-82.4%
6M
-79.4%
1M
-21.2%
1W
-4.4%
OSR
OSR Holdings, Inc.
Peer
5Y
-94.6%
3Y
-94.6%
1Y
-62.3%
6M
-8.9%
1M
+21.5%
1W
+11.1%
HIN
Vyome Holdings, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-96.1%
6M
-56.8%
1M
-15.1%
1W
+2.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
10.78
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
0.57
P/S Ratio
0.82
EV/Revenue
0.29
EV/EBITDA
7.14
Market Cap
$16.87M

Profitability

Profit margins and return metrics

Profit Margin 5.76%
Operating Margin 9.83%
Gross Margin 30.18%
ROE 4.75%
ROA 0.77%

Growth

Revenue and earnings growth rates

Revenue Growth -16.5%
Earnings Growth -32.0%
Q/Q Revenue Growth N/A
Q/Q Earnings Growth -32.0%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.64
Moderate
Current Ratio
1.85
Good
Quick Ratio
1.53
Excellent
Cash/Share
$3.79

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q3 2025

Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.80x

Quarterly Earnings History

EPS performance vs analyst estimates

2026-01-23
$N/A

Healthcare Sector Comparison

Comparing ZJYL against 528 companies in the Healthcare sector (28 bullish, 156 neutral, 344 bearish)
P/E Ratio
10.78
This Stock
vs
81.62
Sector Avg
-86.8% (Discount)
Return on Equity (ROE)
4.75%
This Stock
vs
-92.94%
Sector Avg
-105.1% (Below Avg)
Profit Margin
5.76%
This Stock
vs
-16.56%
Sector Avg
-134.8% (Weaker)
Debt to Equity
0.64
This Stock
vs
2.75
Sector Avg
-76.8% (Less Debt)
Revenue Growth
-16.5%
This Stock
vs
131.76%
Sector Avg
-112.5% (Slower)
Current Ratio
1.85
This Stock
vs
4.62
Sector Avg
-59.9% (Weaker)

Similar Companies

Peer comparison within the same industry

ZJYL Jin Medical...
BEARISH
Mkt Cap
$17M
P/E
10.8
ROE
4.8%
Price
$2.15
LPCN Lipocine Inc.
BEARISH
Mkt Cap
$17M
P/E
-
ROE
-54.3%
Price
$2.38
 Compare with ZJYL
GNTA Genenta Science S.p.A.
BEARISH
Mkt Cap
$16M
P/E
-
ROE
-38.0%
Price
$0.68
 Compare with ZJYL
OSRH OSR Holdings, Inc.
BEARISH
Mkt Cap
$18M
P/E
-
ROE
-20.0%
Price
$0.55
 Compare with ZJYL
HIND Vyome Holdings, Inc.
BEARISH
Mkt Cap
$15M
P/E
-
ROE
-%
Price
$2.19
 Compare with ZJYL

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F
ANNUAL REPORT
2026-02-10

ZJYL filed its annual report on Form 20-F on February 10, 2026. Specific financial highlights and risk factors were not provided in the available metadata.

20-F
ANNUAL REPORT
2025-01-24

ZJYL filed its annual report on Form 20-F on January 24, 2025. Due to the absence of detailed excerpts, specific financial highlights and risk factors are not available for summary.

20-F
ANNUAL REPORT
2024-04-26

ZJYL filed its Form 20-F annual report on April 26, 2024, providing a comprehensive overview of its yearly financial performance. The filing details the company's financial highlights and outlines the primary operational and market risks associated with its business.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning ZJYL from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile